Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
2 investors
Nanocrine develops nanoplasmonic biosensor chips that let cell biology researchers image protein secretions from living cells in real time, without labels, using standard live-cell microscopes. Its single-use biochips apply surface plasmon resonance sensing to map extracellular secretions spatially, functioning like a real-time, microscope-based ELISA.
2 investors
Nanome provides a conversational, AI-assisted platform for exploring molecular structures across web and XR, letting researchers load, build, edit, and score structures using natural language and 300+ scientific tools. It is aimed at pharmaceutical and chemistry R&D teams working with 3D molecular data.
2 investors
Nanomik develops microencapsulation ("Microsome") technology and biological active substances of botanical and microbial origin for fungicidal and insecticidal agricultural products used in crop protection and plant nutrition. The company serves the food and agriculture sector, handling R&D, field trials, formulation, production, and regulatory registration of its products.
2 investors
Nanopath is developing a molecular diagnostic platform for point-of-care disease diagnosis, with a focus on women's health. The company builds novel diagnostic technologies aimed at scalable, accessible testing.
2 investors
Nanophage Technologies develops biological nanorod scaffolds for diagnostic assay applications, enabling enhanced detection and sensitivity in clinical and research settings. The company serves diagnostics manufacturers, pharmaceutical discovery organizations, and clinical laboratories.
2 investors
Nano PharmaSolutions develops NanoTransformer, a patented nanodrug manufacturing platform that improves drug solubility and bioavailability, and delivery systems such as Nano-CNS for neurotherapeutics via nasal spray. The company applies its technology to drug-device combination products for the pharmaceutical industry.
2 investors
NanoPhoria is a life sciences company that raised an €83.5 million Series A round. The page focuses on its investors and does not detail its specific product or technology.
2 investors
Nanostics is a precision health company developing non-invasive diagnostic tests and medical devices that use machine learning to detect and assess aggressive cancers such as prostate cancer, aiming to improve diagnosis and healthcare decisions. It serves clinicians and patients in the cancer diagnostics field.
2 investors
NanoString (part of Bruker Spatial Biology) develops instruments and assays for spatial biology and gene expression analysis, including single-cell and subcellular spatial transcriptomics, proteomics, and multiomics. Its systems serve researchers in oncology, biomarker discovery, neuroscience, and translational and clinical research.
2 investors
Nanovery develops DNA-based nanorobotic sensors that quantify nucleic acid sequences, such as RNA therapeutics and biomarkers, in liquid samples using a standard plate reader. The platform serves biotechnology research and therapeutic analysis workflows.
2 investors
Nat4Bio develops biotechnological solutions that preserve food using naturally-derived microorganisms, reducing food waste and chemical inputs in agriculture. The company serves food producers and supply chains aiming to extend shelf life while minimizing environmental impact.
2 investors
Natáur uses a synthetic biology platform that engineers microbes to produce naturally occurring compounds through fermentation, with its first product being bio-based taurine sold as a ready-to-use ingredient. The company applies metabolic engineering and fermentation to create sustainable bio-based nutrients for human and animal wellness.
2 investors
Native Traits recovers naturally occurring genetic traits from heritage crop varieties and incorporates them into hybrid seeds to improve yield, drought tolerance, and heat resilience. The company works with seed company partners to produce and market branded hybrids under the AgResilient line.
2 investors
Naturannova develops sustainable ingredients using science and technology, working to change how ingredients are produced. The company operates in the biotechnology space with a focus on sustainability.
2 investors
Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
2 investors
NAVAN develops a non-perturbative intracellular delivery technology that transports a wide range of cargo types into primary cell types while preserving cell viability and function. The company applies this platform to cell and gene therapy development across multiple indications through strategic partnerships.
2 investors
Navitas Life Sciences is a global clinical research partner providing clinical, regulatory, safety, and data management solutions to pharmaceutical, biotech, and federal agencies for drug development and patient safety. The company combines industry expertise with proprietary technology platforms to accelerate clinical trials and regulatory processes.
2 investors
Nbryo develops reproductive biotechnology solutions for livestock breeding, specifically focused on cattle embryo production and assisted reproductive technologies to improve genetic outcomes and sustainability in the dairy and beef industries.
2 investors
Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.
2 investors
Nectin Therapeutics develops novel monoclonal antibodies and antibody-drug-conjugates to treat difficult-to-treat cancers by targeting immune evasion mechanisms. The company is a biotech firm with a pipeline focused on oncology immunotherapy, including its lead candidate NTX1088 currently in clinical trials.
2 investors
Nectome provides cryogenic preservation of the human body and brain shortly after legal death, aiming to preserve neural structure in sufficient detail that future revival may become theoretically possible. The service targets individuals at end-of-life seeking experimental preservation as a potential pathway to future recovery.
2 investors
Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
2 investors
NeoEarth develops performance improvements for industrial microalgae strains, combining microalgae biology research with cultivation and production process development. It works to scale industrial collaborations and partnerships around microalgae engineering.
2 investors